Tapinarof Improved Outcomes and Sleep for Patients and Families in Two Phase 3 Atopic Dermatitis Trials in Adults and Children

By sjmartinez • January 9, 2025

Simpson EL, Hebert AA, Browning J, Serrao RT, Sofen H, Brown PM, Piscitelli SC, Rubenstein DS, Tallman AM. Tapinarof Improved Outcomes and Sleep for Patients and Families in Two Phase 3 Atopic Dermatitis Trials in Adults and Children. Dermatol Ther (Heidelb). 2025 Jan 7. doi: 10.1007/s13555-024-01318-6. Epub ahead of print. PMID: 39777610.

Tags: atopic dermatitis, Dermatology, Family impact, Olive View DoM, patient-reported outcomes, Publications, Quality of Life, Sleep improvement, Tapinarof cream 1% once daily, Topical aryl hydrocarbon receptor agonist

Gender differences in pain interference with daily activities and functional impairment among patients with hidradenitis suppurativa: A population-based study in the United States

Kingston P, Peterson H, Lee K, Huang MY, Yee D, Korouri E, Armstrong AW. Gender differences in pain interference with daily activities and functional impairment[...]

Artificial Intelligence and Dermatology

Wongvibulsin S, Lee I. Artificial Intelligence and Dermatology. JAMA Dermatol. 2025 Jan 8. doi: 10.1001/jamadermatol.2024.4645. Epub ahead of print. PMID: 39774621.

Lebrikizumab is associated with improvements in patient-reported symptoms and quality-of-life measures across Eczema Area and Severity Index response categories: pooled results from phase-3 randomized ADvocate1 and ADvocate2 studies in patients with moderate-to-severe atopic dermatitis

Blauvelt A, Kircik L, Schlesinger T, Pierce E, Burge R, Behling M, Atwater AR, ElMaraghy H, Armstrong A. Lebrikizumab is associated with improvements in patient-reported[...]